Actively Recruiting
Genomic Profiles Analysis in Children, Adolescents and Young Adult With Sarcomas
Led by Azienda Ospedaliera Ospedale Infantile Regina Margherita Sant'Anna · Updated on 2023-03-29
120
Participants Needed
10
Research Sites
417 weeks
Total Duration
On this page
Sponsors
A
Azienda Ospedaliera Ospedale Infantile Regina Margherita Sant'Anna
Lead Sponsor
A
Associazione Italiana Ematologia Oncologia Pediatrica
Collaborating Sponsor
AI-Summary
What this Trial Is About
Bone and soft tissue sarcomas represent about 7-12% of all pediatric cancer and are a heterogeneous group of tumors arising in connective tissues embryologically derived from the mesenchyme. For some of these tumors relapse and mortality rates are still significantly high. Therefore, further studies are needed to better understand pathogenetic processes underlying sarcomas to offer new and more effective treatments. Next generation sequencing (NGS) has opened new frontiers for cancer research allowing to identify somatic or constitutional mutations known or yet unknown with the aim to better understand carcinogenesis. The establishment of the genomic profile of the tumor could also help clinicians to personalize patients treatment based on their genetic and molecular alterations.
CONDITIONS
Official Title
Genomic Profiles Analysis in Children, Adolescents and Young Adult With Sarcomas
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with histologically confirmed Osteosarcoma, Ewing Sarcoma or Synovial Sarcoma at first diagnosis.
- Patients with confirmed relapsed/refractory Osteosarcoma, Ewing Sarcoma or Synovial Sarcoma.
- Written informed consent signed by the patient, or parents or legal representative to perform molecular analysis of the tumor sample.
- Patients aged 64 years.
- Pathological review of tumor samples.
- Availability of fresh tumor sample from newly diagnosed or relapsed/refractory cancer and 10 ml of EDTA peripheral blood sample. Centralization of paraffin-embedded tumor sample might be optional.
You will not qualify if you...
- Known history of active HIV, HCV, or HBV infection.
- Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient undergoing surgery biopsy or the quality of the data.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 10 locations
1
AOU Città della Salute e della Scienza di Torino - Presidio Infantile Regina Margherita
Torino, Turin, Italy, 10126
Actively Recruiting
2
Istituto Ortopedico Rizzoli
Bologna, Italy
Actively Recruiting
3
Policlinico S.Orsola-Malpighi
Bologna, Italy
Actively Recruiting
4
Azienda ospedaliero-universitaria Meyer
Florence, Italy
Actively Recruiting
5
Istituto Giannina Gaslini
Genova, Italy
Actively Recruiting
6
Istituto Nazionale Tumori
Milan, Italy
Actively Recruiting
7
Presidio Ospedaliero Gaetano Pini | ASST Pini-CTO
Milan, Italy
Suspended
8
Fondazione I.R.C.C.S. Policlinico San Matteo
Pavia, Italy
Actively Recruiting
9
Istituti fisioterapici Ospitalieri - Istituto Tumori Regina Elena e Istituto Dermatologico San Gallicano
Roma, Italy
Active, Not Recruiting
10
IRCCS materno infantile Burlo Garofolo
Trieste, Italy
Actively Recruiting
Research Team
E
Elisa Tirtei, MD
CONTACT
C
Celeste Cagnazzo, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here